drugset / Trial / NCT03386214
Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis
Non-randomizedSequentialOpen-labelTreatment
Summary
Based on the investigators' preclinical data, the combination of pevonedistat and ruxolitinib may provide greater clinical responses in patients with myelofibrosis compared to ruxolitinib monotherapy via inhibition of NFκB in addition to JAK-STAT signaling.
Timeline
- Start
- 2018-04-23
- Primary completion
- 2021-09-12
- Completion
- 2021-10-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pevonedistat | Small molecule | 5 mg/m2 | Intravenous |
| Subject | Pevonedistat | Small molecule | 10 mg/m2 | Intravenous |
| Subject | Pevonedistat | Small molecule | 20 mg/m2 | Intravenous |
| Background | Ruxolitinib | Small molecule | — | — |